EU Prepares To Release Major Pharma Legislative Overhaul

The much heralded – and oft delayed – revision of the EU pharmaceutical legislative framework is about to be published. R&D-based pharma firms as well as generic and biosimilar companies will be keeping a close eye on proposals such as reductions in regulatory data protection and market exclusivity periods.